REGENXBIO's economics remain hostage to milestone revenue recognition, with quarterly revenue swinging from $6.4M in 2026Q1 to $108.0M in 2026Q2 and gross margin swinging from -107.9% to 99.0%, suggesting the 2026Q2 net income of $22.7M reflects timing rather ...
Price trend, volume and key moving averages
Trailing total returns as of 10/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | $0.43+446.2% vs $0.08 | $108M+10.6% vs $98M |
Q2 2026 May 14, 2026 | -$1.72-26.5% vs -$1.36 | $6M-75.3% vs $26M |
Q2 2026 Mar 5, 2026 | -$1.30-28.7% vs -$1.01 | $30M-31.0% vs $44M |
Q4 2025 Nov 6, 2025 | -$1.20+13.0% vs -$1.38 | $30M-49.8% vs $59M |
REGENXBIO NASDAQ: RGNX outlined its clinical, manufacturing and commercialization plans for sura-vec, an investigational one-time subretinal gene therapy for wet age-related macular degeneration, or wet AMD, during a company event featuring retina specialists and executives.
REGENXBIO Inc. (RGNX) Discusses Clinical Program Progress and Commercial Outlook in Wet AMD and Rare Diseases Transcript
Event to include clinical program overview and perspectives from leading retina specialists ahead of topline pivotal data readout anticipated in 4Q 2026 ROCKVILLE, Md., Oct. 12, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will host an investor event at 1:00 p.m.
Majority of Dose Level 3 participants with NPDR demonstrated a > 2-step DRSS improvement at 3 years post-one-time, in-office sura-vec gene therapy treatment, with no vision-threatening events and no additional treatment for diabetic retinopathy No IOI observed with short-course prophylactic topical steroids ROCKVILLE, Md., Sept. 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced positive long-term follow-up data from the Phase II ALTITUDE® study of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) using suprachoroidal delivery.
Benchmark RGNX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for REGENXBIO Inc. (RGNX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $6.68 | $345.34M | -1.78 | 104.54% | -113.75% | -107% | — | |
| $0.07 | $27.84M | -0.15 | -31.57% | -356.89% | — | — | |
| $2.29 | $250.05M | -1.14 | — | — | -5.76% | — | |
| $311.50 | $9.18B | 45.54 | 33.94% | 54.82% | 19.34% | — | |
| $17.73 | $1.87B | -2.49 | 15.58% | -6.93% | -9.96% | — | |
| $15.65 | $1.54B | -2.68 | 20.13% | -81.79% | — | — |
REGENXBIO Inc. (RGNX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
REGENXBIO Inc. (RGNX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 20, 2026·SEC
Jun 29, 2026·SEC
Get notified when RGNX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
REGENXBIO Inc. (RGNX) stock FAQ — growth, dividends, profitability & financials explained
REGENXBIO Inc. (RGNX) reported $174.5M in revenue for fiscal year 2025. This represents a 2766% increase from $6.1M in 2013.
REGENXBIO Inc. (RGNX) grew revenue by 104.5% over the past year. This is strong growth.
REGENXBIO Inc. (RGNX) reported a net loss of $196.4M for fiscal year 2025.
REGENXBIO Inc. (RGNX) has a return on equity (ROE) of -107.0%. Negative ROE indicates the company is unprofitable.
REGENXBIO Inc. (RGNX) had negative free cash flow of $249.7M in fiscal year 2025, likely due to heavy capital investments.
